HedgeCo.Net — San Mateo-based BigHat Biosciences on September 24, 2026 announced a $75 million Series C co-led by DFJ Growth and Premji Invest, bringing total funding raised to about $223 million, according to the company’s Business Wire release syndicated on BioSpace and Axios Pro Biotech coverage. Catalio Capital Management, LG Technology Ventures, Sigmas Group and existing investors including 8VC, Andreessen Horowitz, Amgen Ventures, Eli Lilly and Company, Merck Global Health Innovation Fund and Section 32 participated.
Proceeds support advancement of BigHat’s clinical-stage pipeline — including CDH17 ADC BHB810, which has dosed a first Phase 1 patient, and CEACAM6 T-cell engager BHB299 nearing completion of preclinical development — and growth of its AI-plus-autonomous-experimentation platform for rapid protein design.
CEO and co-founder Peyton Greenside said the financing advances both the pipeline of BigHat-designed therapeutics and the data platform that powers frontier models for protein design.
For protein-AI venture trackers, the hard marks are the $75 million Series C, DFJ Growth and Premji Invest co-leads, ~$223 million cumulative funding, San Mateo base, and clinical/preclinical markers for BHB810 and BHB299. Do not invent a round valuation beyond what the cited releases disclose.